ON-DEMAND webinar: Intrinsic and acquired resistance to EGFR TKIs: new therapies on the horizon

Learning objectives:         

After attending this symposium, participants should be able to:

• Highlight the importance of intrinsic and acquired EGFR resistance mutations in NSCLC and how this can impact patient outcomes
• Understand the increasing role of genetic and molecular profiling and biomarkers in tailoring therapy
• Describe how current and future research in the treatment of NSCLC may drive therapeutic decisions for patients with specific activating and resistance EGFR mutations

Steering Committee:

• Pilar Garrido (Spain)
• Marina Garassino (Italy) 

Faculty:

• Benjamin Besse (France)
• Lecia Sequist (USA) 
• Matthew Krebs (UK)
• Zosia Piotrowska (USA)

This educational activity has been awarded 2 CPD points by CPDUK, a globally recognised provider of CPD.